Scholars Central

Research articlePublished 17 Nov 2018

Kolaviron protects against cisplatin-induced hepatic and renal oxidative damage in rats

Authors: Tebekeme Okoko, Solomon Ameniyegba Ndoni

Oxidants and Antioxidants in Medical Science

Volume 7 · Issue 2 · Pages 34–41

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Kolaviron is an important bi-flavonoid complex isolated from Garcinia kola seeds which has been reported to possess significant bioactivities. Cisplatin is an antineoplastic drug, but tissue damage is a limiting factor to its chemotherapy. The effect of kolaviron on cisplatin-induced alterations of some biochemical parameters in rats was investigated. The research study included a control group (group I) that received neither cisplatin nor kolaviron while group II received only kolaviron (100 mg/kg/day) orally for the duration of the experiment. Rats in group III were given cisplatin (10 mg/kg/day) for three consecutive days intraperitoneally. In addition to the injection of cisplatin, rats in group IV were orally given kolaviron at 100 mg/kg/day for six consecutive days prior to the treatment with cisplatin, and for 3 days simultaneously with cisplatin. However, animals in group V were given kolaviron at 200 mg/kg/day for six consecutive days prior to the treatment with cisplatin, and for 3 days simultaneously with cisplatin. Thereafter, rats were anesthetized, dissected; serum and tissues were collected and analyzed. The intraperitoneal-administration of cisplatin (10 mg/kg) caused a significant increase in the serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, blood urea nitrogen (Urea), and creatinine indicative of liver and kidney damage. Cisplatin also increased the levels of thiobarbituric acid reactive species, tumor necrosis factor-alpha, and interleukin-6, while significantly reducing the expression of superoxide dismutase (SOD) and catalase (CAT) in both liver and kidney. However, oral administration of kolaviron (100 and 200 mg/kg) for 6 days prior and 3 days co-treatment with cisplatin significantly reversed the cisplatin-induced alterations close to the control levels. Apart from the expression of SOD and CAT in the liver, the effect of kolaviron was dose-dependent (p < 0.05). Treating the rats with kolaviron (100 mg/kg) alone only significantly enhanced the expression of SOD and CAT in the liver over control (p < 0.05). The results reveal kolaviron as an effective chemoprotective agent against cisplatin-induced tissue damage in rats which can be exploited pharmacologically.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Oxidants and Antioxidants in Medical Science.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalOxidants and Antioxidants in Medical Science
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Tebekeme Okoko”
  • BylineArticles whose byline prints “Solomon Ameniyegba Ndoni”